Consensus Protagonist Therapeutics, Inc.

Stocks

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-09 EDT			5-day change	1st Jan Change
145.09 ^USD	-0.58%		-0.68%	+66.12%

09-09	Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10:40 AM
08-31	Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says	MT

Evolution of the Average Target: Protagonist Therapeutics, Inc.

Evolution of the Target Price: Protagonist Therapeutics, Inc.

Changes in Analyst Recommendations: Protagonist Therapeutics, Inc.

085a53da941098d126d41ef.VoakJf9w-_YzrYZjUOdF6w__omnMqpQfMArtKY-UOvs.P8HIEJ0ImbRm3OwBPYAynUe0lDGH_MR7f1-Ecd-iXI5k4O9rkjW5h3XHyw~0a0d2a099f4f66833f213d8189a25479

Analysts' recommendations: Protagonist Therapeutics, Inc.

08-31	Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says	MT
08-31	Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept	MT
08-31	Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says	MT
08-11	Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says	MT
08-10	Goldman Sachs Upgrades Protagonist Therapeutics to Buy From Neutral, Adjusts PT to $186 From $110	MT
08-10	Wedbush Adjusts PT on Protagonist Therapeutics to $173 From $118, Keeps Outperform Rating	MT
08-10	Truist Adjusts Price Target on Protagonist Therapeutics to $170 From $145, Maintains Buy Rating	MT
07-07	Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating	MT
05-06	Wedbush Adjusts Price Target on Protagonist Therapeutics to $118 From $112, Maintains Outperform Rating	MT
04-15	Truist Raises Price Target on Protagonist Therapeutics to $121 From $110, Keeps Buy Rating	MT
03-19	Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says	MT
03-19	Wedbush Raises Price Target on Protagonist Therapeutics to $112 From $100, Keeps Outperform Rating	MT
03-02	Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating	MT
01-05	Truist Adjusts Price Target on Protagonist Therapeutics to $110 From $88, Maintains Buy Rating	MT
25-10-28	Wedbush Raises Price Target on Protagonist Therapeutics to $86 From $70, Keeps Outperform Rating	MT
25-10-28	Truist Raises Price Target on Protagonist Therapeutics to $88 From $76, Keeps Buy Rating	MT
25-10-27	Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial	MT
25-10-10	Johnson & Johnson in Talks to Acquire Protagonist Therapeutics, WSJ Reports	MT
25-10-08	Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says	MT
25-09-17	J&J's experimental psoriasis drug shows promise against Bristol's treatment	RE
25-09-17	Barclays Initiates Protagonist Therapeutics at Overweight	MT
25-09-12	Leerink Partners Initiates Protagonist Therapeutics at Outperform With $73 Price Target	MT
25-06-17	Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target	MT
25-03-11	Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating	MT
25-03-10	Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PROTAGONIST THERAPEUTICS, INC.					+20.4%
	LONZA GROUP AG					+27.91%
	REVOLUTION MEDICINES, INC.					+20.96%
	IQVIA HOLDINGS INC.					+7.51%
	BEONE MEDICINES AG					+23.2%
	CELLTRION, INC.					+46.49%
	ASCENDIS PHARMA A/S					+20.62%
	MEDPACE HOLDINGS, INC.					-0.76%
	EUROFINS SCIENTIFIC SE					+1.84%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+0.95%
	Average					+16.91%
	Weighted average by Cap.					+20.14%